News from janssen r

Jun 24, 2014, 06:58 ET

Fighting for Their Lives: Economist Intelligence Unit Report Finds Patient Groups Lead Global Efforts to Address Hepatitis C

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C...

Jun 18, 2014, 08:30 ET

Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A

Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for...

Jun 18, 2014, 07:59 ET

The Satisfaction Project challenges Canadians with psoriasis and psoriatic arthritis to take control and live better

~Expert panel shares tips, encouraging patients to take a 360° approach to managing their disease and to not give up until they're...

Jun 16, 2014, 17:00 ET

New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies

 Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term...

Jun 12, 2014, 06:00 ET

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and...

Jun 10, 2014, 08:56 ET

Janssen to Present Latest Data for Type 2 Diabetes Treatment INVOKANA® (canagliflozin) at American Diabetes Association 74th Scientific Sessions®

 Janssen Research & Development, LLC (Janssen) announced today that 15 presentations on INVOKANA® (canagliflozin) will be made at the...

Jun 05, 2014, 09:58 ET

La Comisión Europea aprueba SYLVANT® (siltuximab) como tratamiento para la enfermedad de Castleman multicéntrica (MCD)

  - La Comisión Europea aprueba SYLVANT® (siltuximab) como tratamiento para los pacientes con enfermedad de Castleman...

Jun 05, 2014, 09:31 ET

La Commission Européenne approuve l'utilisation du SYLVANT® (siltuximab) dans le traitement de la maladie de Castleman multicentrique (MCM)

  Premier traitement approuvé en Europe pour la prise en charge de la MCM        Janssen-Cilag...

Jun 05, 2014, 09:28 ET

Die Europäische Kommission erteilt die Zulassung für SYLVANT® (Siltuximab) zur Behandlung von Patienten mit der multizentrischen Castleman-Krankheit (MCD)

  Erste Behandlung für das Management von MCD in Europa zugelassen    Janssen-Cilag International NV ("Janssen") gab heute...

Jun 02, 2014, 08:30 ET

IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)

 Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary...

May 31, 2014, 07:33 ET
May 31, 2014, 07:31 ET

Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia

Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA®) suggest continued durable responses in...

May 14, 2014, 17:12 ET

Janssen to Showcase Growing Body of Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50th Annual...

May 14, 2014, 08:00 ET
May 13, 2014, 09:00 ET

Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Submitted to the U.S. FDA for the Treatment of Schizoaffective Disorder

Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting...

May 09, 2014, 12:15 ET

Janssen anuncia la colaboración ampliada con la asociación internacional para microbicidas

- Janssen anuncia la colaboración ampliada con la asociación internacional para microbicidas de cara al desarrollo y...

May 08, 2014, 18:46 ET
May 08, 2014, 04:00 ET

Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV

 Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for...

May 07, 2014, 07:45 ET

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer